Marshall John L
Division of Hematology/Oncology, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC 20007, USA.
Clin Colorectal Cancer. 2008 Dec;7 Suppl 2:S63-6. doi: 10.3816/CCC.2008.s.010.
New surgical techniques and new systemic treatments have come together to increase the number of patients with metastatic colorectal cancer who have been cured. There is great hope that new targeted agents will further increase our success, both through improved therapeutic outcomes and better selection of patients for this more invasive and aggressive approach. A summary of this current clinical data is presented herein to establish our current standards and to guide us toward our future goals. We are increasingly managing patients with a multidisciplinary approach, a critical element in our success. Biologic therapies will continue to play an important role in the management of these patients.
新的外科技术和新的全身治疗方法相结合，增加了已治愈的转移性结直肠癌患者的数量。人们寄厚望于新的靶向药物，通过改善治疗效果以及为这种更具侵入性和攻击性的治疗方法更好地选择患者，进一步提高我们的成功率。本文总结了当前的临床数据，以确立我们目前的标准并指导我们朝着未来的目标前进。我们越来越多地采用多学科方法来管理患者，这是我们成功的关键因素。生物疗法将继续在这些患者的管理中发挥重要作用。
